Episodes

In the final episode, we reflect on investing in artificial intelligence's future with the leader of GV’s Digital Investing Team, Dave Munichiello, who has a long-standing history with AI and robotics.

Our guest for Episode 7 is Dr. Clément Farabet, VP of Research at Google DeepMind. For the past 15 years, Dr. Farabet’s work has been guided by a central mission: figuring out how to build AI systems that can learn on their own — and ultimately redefine how we write software. We discuss the conundr…

In this episode, we’re joined by James DiCarlo, the Peter de Florez Professor of Neuroscience at Massachusetts Institute of Technology and Director of the MIT Quest for Intelligence. Trained in biomedical engineering and medicine, Professor DiCarlo brings a technical mindset to understanding the ma…

In episode 5, we explore how machine learning helped create a map of odor and how that technology will train computers to smell. Anthony Philippakis visits Dr. Alex Wiltschko’s lab at Osmo, where scientists are dedicated to digitizing our sense of smell.

For episode 4, we turn to surgical robots with the help of Dr. Catherine Mohr, President of the Intuitive Foundation, who played an integral role in developing the DaVinci surgical robot system.

In episode 3, we explore how humans will control computers in the future with Dr. Thomas Reardon. Dr. Reardon founded CTRL-Labs and is an early pioneer in exploring the relationship between humans and machines. Now at Meta’s Reality Labs, Dr. Reardon continues his work on non-invasive neural interf…

How do we empower the next generation of LLMs with greater deduction skills and efficiency? We explore a future where introspection is added to LLMs, and Dr. Cui gives broader context to our current thinking about AI’s vast potential.

Dr. Greg Corrado, Distinguished Scientist and Head of Health AI at Google Health, explains how to responsibly introduce AI into healthcare.

For millennia, humans have believed that aging is inevitable. Yet thirty years ago, the work of Professor Cynthia Kenyon and her colleagues showed that a single gene mutation in a worm doubled its lifespan and postponed the diseases of aging. Recent work on the naked mole rat, a mammal like us, has…

What is a thought? Some may think that question is quite abstract, but it has huge implications for science and computer design.

Psychiatry is changing and will be unrecognizable in the next 10-20 years, given our new understanding about the role of brain circuits in the generation of emotions and behavior. This week we talk to Professor Karl Deisseroth, D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral …

This week we speak with Professor David Baker about the enormous scope for making new proteins and how that translates into practical uses to tackle diseases, such as Covid-19.

In the last 20 years or so, many new cancer treatments have emerged that provide greater precision and targeting of cancer cells. Today, we have a better understanding of the genetic components of cancer. Through novel technology and cutting-edge science, we’re now able to understand how the …

Genome editing holds the potential to be a transformative new therapy, and the pace of progress is truly breathtaking.

In this episode we explore the vastness of the dark genome and why "junk DNA" has been overlooked for so many decades.

Julia Vitarello is the mother of Mila Makovec, and the Founder and CEO of Mila’s Miracle Foundation.

Aviv Regev is a computational biologist and Executive Vice President of Genentech Research and Early Development. She was professor at the Broad Institute of MIT and Harvard and at the Department of Biology of the Massachusetts Institute of Technology, as well as investigator at the Howard Hughes M…

Dr. Amy Abernethy is an oncologist, specialist in palliative care medicine, researcher, previous Professor of Medicine at Duke University School of Medicine, previous Scientific and Medical Chief Officer of Flatiron Health, and previous Principal Deputy Commissioner of the FDA.

David Altshuler is Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals.

Dr. Timothy Yu walks us through his experience running the first "N of 1" drug trial for a young patient with a devastating genetic mutation.

Dr. Krishna Yeshwant is Managing Partner at GV, and a practicing physician at Brigham and Women’s Hospital in Boston.

Theory and Practice speaks with Dr. Caroline Uhler, currently the Henry L. and Grace Doherty associate professor in EECS (Electrical Engineering & Computer Science) and IDSS (Institute for Data, Systems and Society) at MIT, and associate member of the Broad Institute where she is co-director of the…

Theory and Practice speaks with Professor Jennifer Listgarten, Professor in UC Berkeley's Electrical Engineering and Computer Sciences Department (EECS department) and the Center for Computational Biology, and Chan Zuckerberg investigator.

Theory and Practice speaks with Professor Sir Rory Collins, Head of Nuffield Department of Population Health at Oxford University and BHF (British Heart Foundation) Professor of Medicine and Epidemiology. Professor Collins is also Principal Investigator and Chief Executive of the UK Biobank.